ISSN 1673-3770 CN 37-1437/R
山东大学耳鼻喉眼学报 ›› 2024, Vol. 38 ›› Issue (1): 128-137.doi: 10.6040/j.issn.1673-3770.0.2022.535
刘天蔚1,赵博军2
LIU Tianwei1, ZHAO Bojun2
摘要： 视网膜静脉阻塞(retinal vein ocdusion, RVO)作为常见的致盲性视网膜血管性疾病,是引起老年人视力损伤的常见原因。但年轻RVO患者的视力下降,整体影响会对社会危害更大,且常伴随全身性疾病的存在。论文系统回顾了年轻RVO患者在发病机制、危险因素(全身及眼部)、临床特征及影像学表现、治疗方式及预后等方面与老年患者的差异,旨在为年轻RVO人群提供个性化管理。
中图分类号:
| [1] Nalcaci S, Degirmenci C, Akkin C, et al. Etiological factors in young patients with Retinal Vein Occlusion[J]. Pak J Med Sci, 2019, 35(5): 1397-1401. doi:10.12669/pjms.35.5.546 [2] Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders[J]. Prog Retin Eye Res, 2005, 24(4): 493-519. doi:10.1016/j.preteyeres.2004.12.001 [3] Chen TY, Uppuluri A, Zarbin MA, et al. Risk factors for central retinal vein occlusion in young adults[J]. Eur J Ophthalmol, 2021, 31(5): 2546-2555. doi:10.1177/1120672120960333 [4] Dewan KS, Hentati F, Greenlee TE, et al. Age-related differences in presentation and outcomes of anti-VEGF treatment of retinal vein occlusion[J]. Can J Ophthalmol, 2021, 56(2): 96-104. doi:10.1016/j.jcjo.2020.09.004 [5] Eah KS, Kim YN, Park YJ, et al. Central retinal vein occlusion in young patients: clinical characteristics and prognostic factors[J]. Retina, 2021, 41(3): 630-637. doi:10.1097/IAE.0000000000002872 [6] Yau JW, Lee P, Wong TY, et al. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management[J]. Intern Med J, 2008, 38(12): 904-910. doi:10.1111/j.1445-5994.2008.01720.x [7] Sanlés González I, Napal Lecumberri JJ, Pérez-Montes R, et al. Retinal vein occlusion in patients under 50 years. Analysis of vascular risk factors, thrombophilia, carotid ultrasound findings and uncommon aetiologies[J]. Arch Soc Esp Oftalmol(Engl Ed), 2022, 97(8): 443-449. doi:10.1016/j.oftale.2021.12.002 [8] Hirano Y, Suzuki N, Tomiyasu T, et al. Multimodal imaging of microvascular abnormalities in retinal vein occlusion[J]. J Clin Med, 2021, 10(3): 405. doi:10.3390/jcm10030405 [9] Cunha-Vaz J. Mechanisms of retinal fluid accumulation and blood-retinal barrier breakdown[J]. Dev Ophthalmol, 2017, 58: 11-20. doi:10.1159/000455265 [10] Noma H, Yasuda K, Shimura M. Cytokines and the pathogenesis of macular edema in branch retinal vein occlusion[J]. J Ophthalmol, 2019: 5185128. doi:10.1155/2019/5185128 [11] Noma H, Yasuda K, Shimura M. Cytokines and pathogenesis of central retinal vein occlusion[J]. J Clin Med, 2020, 9(11): 3457. doi:10.3390/jcm9113457 [12] Jung SH, Kim KA, Sohn SW, et al. Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion[J]. Invest Ophthalmol Vis Sci, 2014, 55(4): 2290-2296. doi:10.1167/iovs.13-13587 [13] Lee WJ, Kang MH, Seong M, et al. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion[J]. Br J Ophthalmol, 2012, 96(11): 1426-1430. doi:10.1136/bjophthalmol-2012-301913 [14] Noma H, Mimura T, Yasuda K, et al. Role of soluble vascular endothelial growth factor receptors-1 and-2, their ligands, and other factors in branch retinal vein occlusion with macular edema[J]. Invest Ophthalmol Vis Sci, 2014, 55(6): 3878-3885. doi:10.1167/iovs.14-13961 [15] Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia[J]. Ophthalmology, 2010, 117(2): 313-319.e1. doi:10.1016/j.ophtha.2009.07.017 [16] Song PG, Xu YH, Zha MM, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors[J]. J Glob Health, 2019, 9(1): 010427. doi:10.7189/jogh.09.010427 [17] Chang YS, Ho CH, Chu CC, et al. Risk of retinal vein occlusion in patients with diabetes mellitus: a retrospective cohort study[J]. Diabetes Res Clin Pract, 2021, 171: 108607. doi:10.1016/j.diabres.2020.108607 [18] Pacella F, Bongiovanni G, Malvasi M, et al. Impact of cardiovascular risk factors on incidence and severity of Retinal Vein Occlusion[J]. Clin Ter, 2020, 171(6): e534-e538. doi:10.7417/CT.2020.2269 [19] Kujovich JL. Factor V leiden thrombophilia[J]. Genet Med, 2011, 13(1): 1-16. doi:10.1097/GIM.0b013e3181faa0f2 [20] Rothman AL, Thomas AS, Khan K, et al. Central retinal vein occlusion in young individuals: a comparison of risk factors and clinical outcomes[J]. Retina, 2019, 39(10): 1917-1924. doi:10.1097/IAE.0000000000002278 [21] Varga EA, Sturm AC, Misita CP, et al. Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease[J]. Circulation, 2005, 111(19): e289-e293. doi:10.1161/01.CIR.0000165142.37711.E7 [22] Bucciarelli P, Passamonti SM, Gianniello F, et al. Thrombophilic and cardiovascular risk factors for retinal vein occlusion[J]. Eur J Intern Med, 2017, 44: 44-48. doi:10.1016/j.ejim.2017.06.022 [23] Bharathi Devi SR, Suganeswari G, Sharma T, et al. Homocysteine induces oxidative stress in young adult central retinal vein occlusion[J]. Br J Ophthalmol, 2012, 96(8): 1122-1126. doi:10.1136/bjophthalmol-2011-301370 [24] Goh EJH, Goh KY. An unusual case of concurrent central retinal vein and cilioretinal artery occlusion in a healthy patient[J]. Case Rep Ophthalmol, 2021, 12(2): 407-411. doi:10.1159/000513794 [25] Sedlak L, Swierczyńska M, Pojda-Wilczek D. Combined central retinal vein and cilioretinal artery occlusion in a 25-year-old woman [J]. Rom J Ophthalmol, 2022, 66(2): 178-184.. doi: 10.22336/rjo.2022.35 [26] Sinawat S, Bunyavee C, Ratanapakorn T, et al. Systemic abnormalities associated with retinal vein occlusion in young patients[J]. Clin Ophthalmol, 2017, 11: 441-447. doi:10.2147/OPTH.S128341 [27] Romiti GF, Corica B, Borgi M, et al. Inherited and acquired thrombophilia in adults with retinal vascular occlusion: a systematic review and meta-analysis[J]. J Thromb Haemost, 2020, 18(12): 3249-3266. doi:10.1111/jth.15068 [28] Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M,et al. Coagulation disorders and the risk of retinal vein occlusion[J]. Thromb Haemost, 2010, 103(2): 299-305. doi:10.1160/TH09-05-0331 [29] Borgman CJ. Concomitant multiple myeloma spectrum diagnosis in a central retinal vein occlusion: a case report and review[J]. Clin Exp Optom, 2016, 99(4): 309-312. doi:10.1111/cxo.12319 [30] Dammacco R, Lisch W, Kivelä TT, et al. The spectrum of ocular manifestations in patients with waldenström's macroglobulinemia[J]. Ocul Immunol Inflamm, 2022, 30(7/8): 1659-1668. doi:10.1080/09273948.2021.1933068 [31] Yang V, Turner LD, Imrie F. Central retinal vein occlusion secondary to severe iron-deficiency anaemia resulting from a plant-based diet and menorrhagia: a case presentation[J]. BMC Ophthalmol, 2020, 20(1): 112. doi:10.1186/s12886-020-01372-6 [32] Huggins AB, Garg SJ, Sando RS. Central retinal vein occlusion in hereditary spherocytosis[J]. RETINAL Cases Brief Rep, 2015, 13. doi:10.1097/icb.0000000000000247 [33] Kumar A, Shankar S, Kochhar D, et al. Acute myeloid leukemia presenting as unilateral central retinal vein occlusion[J]. GMS Ophthalmol Cases, 2022, 12: Doc15. doi:10.3205/oc000202 [34] Caprini JA, Glase CJ, Anderson CB, et al. Laboratory markers in the diagnosis of venous thromboembolism[J]. Circulation, 2004, 109(12 Suppl 1): I4-I8. doi:10.1161/01.CIR.0000122869.59485.36 [35] Zhu W, Wu Y, Xu M, et al. Antiphospholipid antibody and risk of retinal vein occlusion: a systematic review and meta-analysis[J]. PLoS One, 2014, 10(4): e0122814. doi:10.1371/journal.pone.0122814 [36] João MD, Costa JV, Santos GC, et al. Retinal vein and artery occlusion as the first manifestation of primary antiphospholipid syndrome in a pediatric patient[J]. Arq Bras Oftalmol, 2022: S0004-S27492022005008207. doi:10.5935/0004-2749.2021-0431 [37] Yen YC, Weng SF, Chen HA, et al. Risk of retinal vein occlusion in patients with systemic lupus erythematosus: a population-based cohort study[J]. Br J Ophthalmol, 2013, 97(9): 1192-1196. doi:10.1136/bjophthalmol-2013-303265 [38] Nag TC, Wadhwa S. Vascular changes of the retina and choroid in systemic lupus erythematosus: pathology and pathogenesis[J]. Curr Neurovasc Res, 2006, 3(2): 159-168. doi:10.2174/156720206776875821 [39] Dunn JP, Yamashita A, Kempen JH, et al. Retinal vascular occlusion in patients infected with human immunodeficiency virus[J]. Retina, 2005, 25(6): 759-766. doi:10.1097/00006982-200509000-00012 [40] Mahyudin M, Choo MM, Ramli NM, et al. Ocular tuberculosis initially presenting as central retinal vein occlusion[J]. Case Rep Ophthalmol, 2010, 1(1): 30-35. doi:10.1159/000317605 [41] O'Donovan C, Vyas N, Ghanchi F. Retinal vein occlusion with COVID-19: a case report and review of literature[J]. Ocul Immunol Inflamm, 2022. doi:10.1080/09273948.2022.2032196 [42] Takacs A, Ecsedy M, Nagy ZZ. Possible COVID-19 MRNA vaccine-induced case of unilateral central retinal vein occlusion[J]. Ocul Immunol Inflamm, 2022. doi:10.1080/09273948.2022.2094811 [43] Feltgen N, Ach T, Ziemssen F, et al. Retinal vascular occlusion after COVID-19 vaccination: more coincidence than causal relationship? data from a retrospective multicentre study[J]. J Clin Med, 2022, 11(17): 5101. doi:10.3390/jcm11175101 [44] Nicolo' M, Artioli S, La Mattina GC, et al. Branch retinal artery occlusion combined with branch retinal vein occlusion in a patient with hepatitis C treated with interferon and ribavirin[J]. Eur J Ophthalmol, 2005, 15(6): 811-814. doi:10.5301/EJO.2008.4623 [45] Moussa O, Chen RWS. Central retinal vein occlusion associated with creatine supplementation and dehydration[J]. Am J Ophthalmol Case Rep, 2021, 23: 101128. doi:10.1016/j.ajoc.2021.101128 [46] Prabhudesai A, Shetty S, Ghosh K, et al. Multiple heritable and acquired risk factors in a case of recurrent retinal vein occlusion[J]. J Assoc Physicians India, 2018, 66(3): 81-83 [47] Aggarwal RS, Mishra VV, Aggarwal SV. Oral contraceptive pills: a risk factor for retinal vascular occlusion in in-vitro fertilization patients[J]. J Hum Reprod Sci, 2013, 6(1): 79-81. doi:10.4103/0974-1208.112389 [48] Ha MJ, Han K, Jung Y, et al. Is retinal vein occlusion associated with depression symptoms?: a nationwide cohort study[J]. Medicine(Baltimore), 2021, 100(32): e26937. doi:10.1097/MD.0000000000026937 [49] Yin X, Li JQ, Zhang BY, et al. Association of glaucoma with risk of retinal vein occlusion: a meta-analysis[J]. Acta Ophthalmol, 2019, 97(7): 652-659. doi:10.1111/aos.14141 [50] Xu K, Wu LL, Ma ZZ, et al. Primary angle closure and primary angle closure glaucoma in retinal vein occlusion[J]. Acta Ophthalmol, 2019, 97(3): e364-e372. doi:10.1111/aos.13879 [51] Kim MJ, Woo SJ, Park KH, et al. Retinal nerve fiber layer thickness is decreased in the fellow eyes of patients with unilateral retinal vein occlusion[J]. Ophthalmology, 2011, 118(4): 706-710. doi:10.1016/j.ophtha.2010.08.028 [52] Kim YN, Shin JW, Park YJ, et al. Glaucoma as a prognostic factor of central retinal vein occlusion: visual and anatomical outcomes and occurrence of ischaemic central retinal vein occlusion[J]. Acta Ophthalmol, 2021, 99(4): e523-e530. doi:10.1111/aos.14608 [53] Ghoghari H, Rizvi SF, Loya H, et al. Axial length, a risk factor for retinal vein occlusion: a case control study[J]. J Pak Med Assoc, 2019, 69(12): 1800-1802. doi:10.5455/JPMA.6579 [54] Szigeti A, Schneider M, Ecsedy M, et al. Association between retinal vein occlusion, axial length and vitreous chamber depth measured by optical low coherence reflectometry[J]. BMC Ophthalmol, 2015, 15: 45. doi:10.1186/s12886-015-0031-1 [55] Satoh S, Itoh C, Nakamura N. A case of frosted branch angiitis associated with retinal vein occlusion as a complication of familial Mediterranean fever[J]. Nippon Ganka Gakkai Zasshi, 2010, 114(7): 621-628 [56] Vofo BN, Amer R. Outer retina rupture from subretinal blood with spontaneous sealing and visual recovery in frosted branch angiitis from familial Mediterranean fever: a case report[J]. Turk J Ophthalmol, 2022, 52(4): 286-290. doi:10.4274/tjo.galenos.2022.69337 [57] Sarpangala S, George NM, Kamath YS, et al. Central retinal vein occlusion secondary to varicella zoster retinal vasculitis in an immunocompetent individual during the COVID-19 pandemic - A case report[J]. Indian J Ophthalmol, 2021, 69(9): 2532-2535. doi:10.4103/ijo.IJO_1644_21 [58] Kopsachilis N, Brar M, Marinescu AI, et al. Central nervous system tuberculosis presenting as branch retinal vein occlusion[J]. Clin Exp Optom, 2013, 96(1): 121-123. doi:10.1111/j.1444-0938.2012.00757.x [59] Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion[J]. Ophthalmology, 2011, 118(1): 119-133.e1-2. doi:10.1016/j.ophtha.2010.04.019 [60] Hayreh SS. Photocoagulation for retinal vein occlusion[J]. Prog Retin Eye Res, 2021, 85: 100964. doi:10.1016/j.preteyeres.2021.100964 [61] Browning DJ. Patchy ischemic retinal whitening in acute central retinal vein occlusion[J]. Ophthalmology, 2002, 109(11): 2154-2159. doi:10.1016/s0161-6420(02)01217-4 [62] Ye PP, Zhu TP, Zheng F, et al. Microvascular comparison in younger and older patients with retinal vein occlusion analyzed by OCT angiography[J]. BMC Ophthalmol, 2021, 21(1): 161. doi:10.1186/s12886-021-01931-5 [63] Paques M, Tadayoni R, Sercombe R, et al. Structural and hemodynamic analysis of the mouse retinal microcirculation[J]. Invest Ophthalmol Vis Sci, 2003, 44(11): 4960-4967. doi:10.1167/iovs.02-0738 [64] Bonnin S, Mané V, Couturier A, et al. New insight into the macular deep vascular plexus imaged by optical coherence tomography angiography[J]. Retina, 2015, 35(11): 2347-2352. doi:10.1097/IAE.0000000000000839 [65] Aref AA, Scott IU, VanVeldhuisen PC, et al. Intraocular pressure-related events after anti-vascular endothelial growth factor therapy for macular edema due to central retinal vein occlusion or hemiretinal vein occlusion: SCORE2 report 16 on a secondary analysis of a randomized clinical trial[J]. JAMA Ophthalmol, 2021, 139(12): 1285-1291. doi:10.1001/jamaophthalmol.2021.4395 [66] Scott IU, Oden NL, VanVeldhuisen PC, et al. Baseline characteristics and outcomes after anti-vascular endothelial growth factor therapy for macular edema in participants with hemiretinal vein occlusion compared with participants with central retinal vein occlusion: study of comparative treatments for retinal vein occlusion 2(SCORE2)report 18[J]. JAMA Ophthalmol, 2022, 140(5): 458-464. doi:10.1001/jamaophthalmol.2022.0352 [67] Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study[J]. Am J Ophthalmol, 2010, 150(3): 310-314. doi:10.1016/j.ajo.2010.03.028 [68] 韩克阳, 于贝贝, 赵博军. 短期视网膜静脉阻塞抗VEGF治疗后黄斑区形态结构分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(5): 129-131. doi:10.6040/j.issn.1673-3770.0.2017.515 HAN Keyang, YU Beibei, ZHAO Bojun. Morphological structure analysis of the macular area after anti-VEGF treatment for short-term retinal vein occlusion[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(5): 129-131. doi:10.6040/j.issn.1673-3770.0.2017.515 [69] Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study[J]. Ophthalmology, 2010, 117(6): 1102-1112.e1. doi:10.1016/j.ophtha.2010.02.021 [70] Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study[J]. Ophthalmology, 2010, 117(6): 1124-1133.e1. doi:10.1016/j.ophtha.2010.02.022 [71] Scott IU, VanVeldhuisen PC, Ip MS, et al. Baseline factors associated with 6-month visual acuity and retinal thickness outcomes in patients with macular edema secondary to central retinal vein occlusion or hemiretinal vein occlusion: SCORE2 study report 4[J]. JAMA Ophthalmol, 2017, 135(6): 639-649. doi:10.1001/jamaophthalmol.2017.1141 [72] Spooner K, Fraser-Bell S, Hong T, et al. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab[J]. Clin Exp Ophthalmol, 2020, 48(1): 53-60. doi:10.1111/ceo.13636 [73] Vader MJC, Schauwvlieghe AME, Verbraak FD, et al. Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion: the bevacizumab to ranibizumab in retinal vein occlusions(BRVO)study, a randomized trial[J]. Ophthalmol Retina, 2020, 4(6): 576-587. doi:10.1016/j.oret.2019.12.019 [74] Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion[J]. Ophthalmology, 2010, 117(6): 1134-1146.e3. doi:10.1016/j.ophtha.2010.03.032 [75] Rezkallah A, Mathis T, Abukhashabah A, et al. Long-term incidence and risk factors of ocular hypertension following dexamethasone-implant injections: the safodex-2 study[J]. Retina, 2021, 41(7): 1438-1445. doi:10.1097/IAE.0000000000003080 [76] Battaglia Parodi M, Iacono P, Sacconi R, et al. Dexamethasone implant for macular edema secondary to central retinal vein occlusion in patients younger than 50 years[J]. Retina, 2015, 35(7): 1381-1386. doi:10.1097/IAE.0000000000000494 [77] Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results[J]. Ophthalmology, 2011, 118(12): 2453-2460. doi:10.1016/j.ophtha.2011.05.014 [78] Georgalas L, Tservakis I, Kiskira EE, et al. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study[J]. Cutan Ocul Toxicol, 2019, 38(4): 330-337. doi:10.1080/15569527.2019.1614020 [79] Jonas JB, Monés J, Glacet-Bernard A, et al. Retinal vein occlusions[J]. Dev Ophthalmol, 2017, 58: 139-167. doi:10.1159/000455278 [80] 唐慧新, 李景景, 邹红. 阈值下微脉冲激光光凝作用机制及临床应用[J]. 山东大学耳鼻喉眼学报,2023,37(3): 143-148. doi:10.6040/j.issn.1673-3770.0.2022.254 TANG Huixin, LI Jingjing, ZOU Hong. GuidanceMechanism and clinical applications of subthreshold diode micropulse laser[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023,37(3): 143-148. doi:10.6040/j.issn.1673-3770.0.2022.254 [81] Terashima H, Hasebe H, Okamoto F, et al. Combination therapy of intravitreal ranibizumab and subthreshold micropulse photocoagulation for macular edema secondary to branch retinal vein occlusion: 6-month result[J]. Retina, 2019, 39(7): 1377-1384. doi:10.1097/IAE.0000000000002165 [82] Opremcak EM, Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases[J]. Retina, 1999, 19(1): 1-5. doi:10.1097/00006982-199901000-00001 [83] Opremcak EM, Bruce RA, Lomeo MD, et al. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases[J]. Retina, 2001, 21(5): 408-415. doi:10.1097/00006982-200110000-00002 [84] Chuang LH, Wang NK, Chen YP, et al. Vitrectomy and panretinal photocoagulation reduces the occurrence of neovascular glaucoma in central retinal vein occlusion with vitreous hemorrhage[J]. Retina, 2013, 33(4): 798-802. doi:10.1097/IAE.0b013e31826af52d [85] DeCroos FC, Shuler RK Jr, Stinnett S, et al. Pars Plana vitrectomy, internal limiting membrane peeling, and panretinal endophotocoagulation for macular edema secondary to central retinal vein occlusion[J]. Am J Ophthalmol, 2009, 147(4): 627-633.e1. doi:10.1016/j.ajo.2008.10.024 [86] Khan FA, Qureshi NA. Pars Plana vitrectomy for resistant cystoid macular edema[J]. J Coll Physicians Surg Pak, 2019, 29(12): 1165-1168. doi:10.29271/jcpsp.2019.12.1165 [87] Kuo JZ, Lai CC, Ong FS, et al. Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality[J]. Retina, 2010, 30(3): 479-484. doi:10.1097/IAE.0b013e3181b9b3a0 [88] Zhang XT, Zhong YF, Xue YQ, et al. Clinical features of central retinal vein occlusion in young patients[J]. Ophthalmol Ther, 2022, 11(4): 1409-1422. doi:10.1007/s40123-022-00534-7 [89] Koh YY, Lai CC, Wu WC, et al. Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2020, 258(7): 1367-1377. doi:10.1007/s00417-020-04679-8 |
| [1] | 唐慧新,李景景,邹红. 阈值下微脉冲激光光凝作用机制及临床应用[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 143-148. |
| [2] | 顾冉冉,李凤娇,焦万珍,崔艳艳,赵博军. 卵磷脂络和碘胶囊辅助治疗视网膜静脉阻塞的临床疗效研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 46-50. |
| [3] | 韩克阳,于贝贝,赵博军. 短期视网膜静脉阻塞抗VEGF治疗后黄斑区形态结构分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(5): 129-131. |
| [4] | 梁倩倩,杨庭骅,赵博军. 光学相干层析血管扫描在视网膜静脉阻塞中的应用[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 139-142. |
| [5] | 韩克阳,王淑雅,焦芮,于贝贝, 赵博军. 视网膜静脉阻塞的发病机制及黄斑水肿的抗-VEGF治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 123-126. |
| [6] | 严晓腾,冯军,康欣乐. 玻璃体腔注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床观察[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 105-108. |
| [7] | 王永波，石安娜，石浔，金昱，刘维锋. 视网膜静脉阻塞患者光感受器细胞层与最佳视力之间的关系[J]. 山东大学耳鼻喉眼学报, 2013, 27(1): 78-80. |
| [8] | 李晋齐1，王静波2，赵靖1. 中药结合激光治疗RVO的临床观察[J]. 山东大学耳鼻喉眼学报, 2010, 24(5): 62-. |
| [9] | 王琳，关娟，周历，盛豫，司艳芳，赵慧英，赵娟. 高脂血症与视网膜静脉阻塞发病的相关性研究[J]. 山东大学耳鼻喉眼学报, 2010, 24(01): 44-46. |
|
||